Trial Profile
Clinical use and outcomes associated with Ceftolozane/Tazobactam in patients with Pseudomonas aeruginosa infections
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Oct 2017
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary)
- Indications Pseudomonal infections
- Focus Therapeutic Use
- 24 Oct 2017 New trial record
- 08 Oct 2017 Results presented at the IDWeek 2017